541
Participants
Start Date
March 27, 2014
Primary Completion Date
July 1, 2016
Study Completion Date
May 27, 2022
Nivolumab
Gemcitabine
Cisplatin
Carboplatin
Paclitaxel
Pemetrexed
Local Institution - 0163, Seoul
Local Institution - 0077, Lausanne
Local Institution - 0087, Vienna
Local Institution - 0044, Brussels
Local Institution - 0126, Budapest
Local Institution - 0052, Ciudad Autonoma de Buenos Aire
Local Institution - 0049, Capital Federal
Local Institution - 0051, Berazategui
Local Institution - 0090, Camperdown
Local Institution - 0055, Edegem
Local Institution - 0062, Leuven
Local Institution - 0072, Fitzroy
Local Institution - 0104, Heidelberg
Local Institution - 0094, Mátraháza
Local Institution - 0116, Debrecen
Local Institution - 0091, Brisbane
Local Institution - 0088, Wels
Local Institution - 0048, Córdoba
Local Institution - 0050, Córdoba
Local Institution - 0071, Elizabeth Vale
Local Institution - 0076, Chur
Local Institution - 0078, Zurich
Local Institution - 0056, Ghent
Local Institution - 0009, New York
Local Institution - 0005, New York
Local Institution - 0157, Taipei
Local Institution - 0075, Athens
Local Institution - 0102, Marseille
Local Institution - 0123, Caen
Local Institution - 0117, Mexico City
Roswell Park Cancer Institute, Buffalo
Local Institution - 0018, Pittsburgh
Local Institution - 0007, Allentown
Local Institution - 0054, Philadelphia
Local Institution - 0002, Philadelphia
Local Institution - 0143, Milan
Local Institution - 0024, Baltimore
Local Institution - 0065, Großhansdorf
Local Institution - 0003, Durham
Local Institution - 0047, Madrid
Local Institution - 0042, Málaga
Local Institution - 0011, Charleston
Local Institution - 0038, Greenville
Northwest Georgia Oncology Center, P.C., Marietta
Local Institution - 0010, Atlanta
Local Institution - 0030, Miami
Local Institution - 0119, Tampere
H. Lee Moffitt Cancer Center, Tampa
Local Institution - 0033, Ocala
Local Institution - 0041, Las Palmas de Gran Canaria
Local Institution - 0100, Rennes
Southern Cancer Center, Inc., Mobile
Local Institution - 0130, Kayseri
Local Institution - 0014, Lexington
Local Institution - 0039, Seville
Local Institution - 0027, Columbus
Local Institution - 0012, Cleveland
Local Institution - 0122, Guadalajara
Local Institution - 0043, Valencia
Local Institution - 0063, Cologne
Local Institution - 0079, Livorno
Local Institution - 0105, Lille
Local Institution - 0118, Vaasa
Local Institution - 0092, Wiesbaden
Local Institution - 0140, Strasbourg
Local Institution - 0064, Heidelberg
Crescent City Research Consortium, LLC, Marrero
Local Institution - 0066, Stuttgart
Local Institution - 0073, Heraklion
Local Institution - 0006, Dallas
Local Institution - 0023, Houston
Cancer Centers of South Texas, San Antonio
University Of Colorado Hosp, Aurora
Local Institution - 0142, Napoli
Local Institution - 0084, Avellino
Banner MD Anderson Cancer Center, Gilbert
Local Institution - 0034, Tucson
Local Institution - 0167, Pontoise
Local Institution - 0074, Bamberg
Local Institution - 0124, Mérida
Local Institution - 0029, Yakima
Local Institution - 0069, Ploieşti
Local Institution - 0068, Cluj-Napoca
Local Institution - 0067, Cluj-Napoca
Local Institution - 0154, Chuo-ku
Local Institution - 0160, Tokyo
Local Institution - 0150, Kitaadachi-gun
Local Institution - 0162, Ota, Gunma
Local Institution - 0149, Sunto-gun
Local Institution - 0146, Nagoya
Local Institution - 0161, Nagoya
Local Institution - 0166, Habikino-shi
Local Institution - 0153, Kobe
Local Institution - 0148, Matsuyama
Local Institution - 0144, Natori-shi
Local Institution - 0016, Stanford
Local Institution - 0020, New Haven
Local Institution - 0037, Chicago
Local Institution - 0036, Boston
Local Institution - 0070, Boston
University Of North Carolina At Chapel Hill, Chapel Hill
Oregon Health & Science University, Portland
Local Institution - 0008, Nashville
Local Institution - 0134, Ijuí
Local Institution - 0133, Porto Alegre
Local Institution - 0135, Barretos
Local Institution - 0086, Calgary
Local Institution - 0115, Hamilton
Local Institution - 0113, Toronto
Local Institution - 0110, Montreal
Local Institution - 0109, Rimouski
Local Institution - 0059, Olomouc
Local Institution - 0061, Ostrava - Poruba
Local Institution - 0058, Prague
Local Institution - 0060, Ústí nad Labem
Local Institution - 0120, Helsinki
Local Institution - 0083, Perugia
Local Institution - 0082, Terni
Local Institution - 0151, Niigata
Local Institution - 0147, Miyakojima-ku
Local Institution - 0145, Ōsaka-sayama
Local Institution - 0152, Sakai
Local Institution - 0159, Akashi, Hyogo
Local Institution - 0165, Sapporo, Hokkaido
Local Institution - 0158, Wakayama
Local Institution - 0045, Amsterdam
Local Institution - 0057, Groningen
Local Institution - 0046, Rotterdam
Local Institution - 0114, Bydgoszcz
Local Institution - 0131, Krakow
Local Institution - 0139, Lodz
Local Institution - 0089, Warsaw
Local Institution - 0093, Wodzisław Śląski
Local Institution - 0155, Gangnam-gu
Local Institution - 0164, Seoul
Local Institution - 0040, Barcelona
Local Institution - 0127, Stockholm
Local Institution - 0125, Uppsala
Local Institution - 0098, London
Local Institution - 0097, Manchester
Local Institution - 0053, Leeds
Lead Sponsor
Collaborators (1)
Ono Pharmaceutical Co. Ltd
INDUSTRY
Bristol-Myers Squibb
INDUSTRY